Sacituzumab govitecan in triple-negative breast cancer

Detalles Bibliográficos
Autores principales: de Nonneville, Alexandre, Goncalves, Anthony, Mamessier, Emilie, Bertucci, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263779/
https://www.ncbi.nlm.nih.gov/pubmed/35813338
http://dx.doi.org/10.21037/atm-22-813
_version_ 1784742821728616448
author de Nonneville, Alexandre
Goncalves, Anthony
Mamessier, Emilie
Bertucci, François
author_facet de Nonneville, Alexandre
Goncalves, Anthony
Mamessier, Emilie
Bertucci, François
author_sort de Nonneville, Alexandre
collection PubMed
description
format Online
Article
Text
id pubmed-9263779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-92637792022-07-09 Sacituzumab govitecan in triple-negative breast cancer de Nonneville, Alexandre Goncalves, Anthony Mamessier, Emilie Bertucci, François Ann Transl Med Editorial Commentary AME Publishing Company 2022-06 /pmc/articles/PMC9263779/ /pubmed/35813338 http://dx.doi.org/10.21037/atm-22-813 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
de Nonneville, Alexandre
Goncalves, Anthony
Mamessier, Emilie
Bertucci, François
Sacituzumab govitecan in triple-negative breast cancer
title Sacituzumab govitecan in triple-negative breast cancer
title_full Sacituzumab govitecan in triple-negative breast cancer
title_fullStr Sacituzumab govitecan in triple-negative breast cancer
title_full_unstemmed Sacituzumab govitecan in triple-negative breast cancer
title_short Sacituzumab govitecan in triple-negative breast cancer
title_sort sacituzumab govitecan in triple-negative breast cancer
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263779/
https://www.ncbi.nlm.nih.gov/pubmed/35813338
http://dx.doi.org/10.21037/atm-22-813
work_keys_str_mv AT denonnevillealexandre sacituzumabgovitecanintriplenegativebreastcancer
AT goncalvesanthony sacituzumabgovitecanintriplenegativebreastcancer
AT mamessieremilie sacituzumabgovitecanintriplenegativebreastcancer
AT bertuccifrancois sacituzumabgovitecanintriplenegativebreastcancer

Ejemplares similares